HIGHLIGHTS
- who: Oliver Sartor from the Oslo University Hospital, Norway Emory University, United States have published the research: Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts, in the Journal: (JOURNAL)
- what: A phase III study (PROSTACT) of 177 Lu-J591 is planned in the mCRPC space post-ARPI but this trial has yet to start accrual (NCT04876651).
- how: The PSMA targeted beta emitter 177 Lu-PSMA-617 was tested in the PHASE III VISION trial .
- future: Clearly more work is needed before a phase III can be launched. Future . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.